Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.26+0.09 (+0.88%)
Close on Nov 11, 2026Market cap $170.12MP/E –Yield –
Sutro Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Sutro Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $144.74M, down 35.1% year over year. For fiscal 2025 it was $166.42M, down 34.0% from the year before. The highest annual figure on record is $252.04M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.42M | -34.0% |
| FY2024 | Dec 31, 2024 | $252.04M | +39.7% |
| FY2023 | Dec 31, 2023 | $180.43M | +31.5% |
| FY2022 | Dec 31, 2022 | $137.17M | +31.4% |
| FY2021 | Dec 31, 2021 | $104.40M | +35.7% |
| FY2020 | Dec 31, 2020 | $76.96M | +17.3% |
| FY2019 | Dec 31, 2019 | $65.61M | +20.9% |
| FY2018 | Dec 31, 2018 | $54.26M | -0.7% |
| FY2017 | Dec 31, 2017 | $54.64M | +25.5% |
| FY2016 | Dec 31, 2016 | $43.55M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $31.70M | -17.3% |
| Q1 FY2026 | Mar 31, 2026 | $36.55M | -29.2% |
| Q4 FY2025 | Dec 31, 2025 | $36.64M | -48.4% |
| Q3 FY2025 | Sep 30, 2025 | $39.85M | -35.8% |
| Q2 FY2025 | Jun 30, 2025 | $38.33M | -38.2% |
| Q1 FY2025 | Mar 31, 2025 | $51.60M | -9.3% |
| Q4 FY2024 | Dec 31, 2024 | $71.04M | +32.1% |
| Q3 FY2024 | Sep 30, 2024 | $62.11M | +36.0% |
| Q2 FY2024 | Jun 30, 2024 | $62.02M | +49.1% |
| Q1 FY2024 | Mar 31, 2024 | $56.88M | +44.4% |
| Q4 FY2023 | Dec 31, 2023 | $53.77M | +24.6% |
| Q3 FY2023 | Sep 30, 2023 | $45.67M | +44.0% |
| Q2 FY2023 | Jun 30, 2023 | $41.59M | +28.6% |
| Q1 FY2023 | Mar 31, 2023 | $39.40M | +31.4% |
| Q4 FY2022 | Dec 31, 2022 | $43.14M | +44.1% |
| Q3 FY2022 | Sep 30, 2022 | $31.71M | +19.2% |
| Q2 FY2022 | Jun 30, 2022 | $32.33M | +27.7% |
| Q1 FY2022 | Mar 31, 2022 | $29.99M | +32.9% |
| Q4 FY2021 | Dec 31, 2021 | $29.93M | +31.6% |
| Q3 FY2021 | Sep 30, 2021 | $26.60M | +37.4% |
| Q2 FY2021 | Jun 30, 2021 | $25.31M | +46.8% |
| Q1 FY2021 | Mar 31, 2021 | $22.56M | +28.1% |
| Q4 FY2020 | Dec 31, 2020 | $22.74M | +30.7% |
| Q3 FY2020 | Sep 30, 2020 | $19.36M | +14.6% |
| Q2 FY2020 | Jun 30, 2020 | $17.24M | +6.8% |
| Q1 FY2020 | Mar 31, 2020 | $17.62M | +16.1% |
| Q4 FY2019 | Dec 31, 2019 | $17.39M | +17.6% |
| Q3 FY2019 | Sep 30, 2019 | $16.90M | +33.7% |
| Q2 FY2019 | Jun 30, 2019 | $16.14M | +17.4% |
| Q1 FY2019 | Mar 31, 2019 | $15.18M | +16.0% |
| Q4 FY2018 | Dec 31, 2018 | $14.79M | -2.3% |
| Q3 FY2018 | Sep 30, 2018 | $12.64M | -7.5% |
| Q2 FY2018 | Jun 30, 2018 | $13.75M | – |
| Q1 FY2018 | Mar 31, 2018 | $13.08M | – |
| Q4 FY2017 | Dec 31, 2017 | $15.14M | – |
| Q3 FY2017 | Sep 30, 2017 | $13.67M | – |
See a number that looks wrong?